Lin Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lin Li has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
Jinglei Hu
6 shared publications- Aditya Bardia
University of California Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, USA
4 shared publications - Alan Wang
Auckland Bioengineering Institute, The University of Auckland, Auckland, New Zealand
4 shared publications - Amal Thomas
Department of Molecular and Computational Biology, USC David and Dana Dornsife College of Letters, Arts and Sciences, University of Southern California, Los Angeles, California
4 shared publications - Bodour Salhia
Department of Translational Genomics, Keck School of Medicine, University of Southern California and Norris Comprehensive Cancer Center, Los Angeles, USA
4 shared publications - Byoung-San Moon
Department of Medical Biotechnology, Yeungnam University, Gyeongsan, Republic of Korea
4 shared publications
Latest Publications
- Open Access
- 1 November 2026
- Published by KEAI Publishing in Genes & Diseases
- Vol. 13  (6)
Proteomic profiling identifies SMARCA1 as a stage-specific epigenetic regulator of colorectal cancer metastasis through MMP modulation
- 1 November 2026
- Published by KEAI Publishing in Genes & Diseases
- Vol. 13  (6)
Open AccessProteomic profiling identifies SMARCA1 as a stage-specific epigenetic regulator of colorectal cancer metastasis through MMP modulation
- 8 July 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69  (14) , 17093-17117
RIMTAC: A Novel Degrader Design Platform by Indirect VHL-Recruitment via RIPK1
Proteolysis-targeting chimeras (PROTACs) have emerged as a transformative approach for targeted protein degradation (TPD). However, their therapeutic potential is limited by the scarcity of diverse E3 ligase ligands. Only a small fraction of more than 600 human E3 ligases are currently amenable to functional PROTAC development. To expand the E3 ligase toolbox, we developed RIPK1-Mediated Targeting Chimeras (RIMTAC). Rather than directly inhibiting VHL, RIMTAC employs a RIPK1 inhibitor to hijack the endogenous RIPK1-VHL complex, recruiting VHL indirectly for TPD. As a proof of concept, we designed RIMTACs targeting BRD4, AKT, and JAK1. These molecules induced potent, concentration- and time-dependent degradation of their targets. Mechanistically, degradation was confirmed to be UPS-dependent and required a quaternary complex of VHL, RIPK1, the target protein, and the RIMTAC molecule. RIMTAC expands the TPD toolbox and offers a promising synergistic strategy for anti-inflammatory therapy.
- 8 July 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69  (14) , 17093-17117
RIMTAC: A Novel Degrader Design Platform by Indirect VHL-Recruitment via RIPK1
Proteolysis-targeting chimeras (PROTACs) have emerged as a transformative approach for targeted protein degradation (TPD). However, their therapeutic potential is limited by the scarcity of diverse E3 ligase ligands. Only a small fraction of more than 600 human E3 ligases are currently amenable to functional PROTAC development. To expand the E3 ligase toolbox, we developed RIPK1-Mediated Targeting Chimeras (RIMTAC). Rather than directly inhibiting VHL, RIMTAC employs a RIPK1 inhibitor to hijack the endogenous RIPK1-VHL complex, recruiting VHL indirectly for TPD. As a proof of concept, we designed RIMTACs targeting BRD4, AKT, and JAK1. These molecules induced potent, concentration- and time-dependent degradation of their targets. Mechanistically, degradation was confirmed to be UPS-dependent and required a quaternary complex of VHL, RIPK1, the target protein, and the RIMTAC molecule. RIMTAC expands the TPD toolbox and offers a promising synergistic strategy for anti-inflammatory therapy.
- 17 June 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69  (13) , 15423-15457
Unique Cysteine-Directed Covalent Inhibition of PRMT1 Suppresses Breast Tumorigenesis
Dysregulation of PRMT1, a key epigenetic enzyme, is strongly implicated in breast cancer pathogenesis. However, developing selective PRMT1 inhibitors has been challenging due to the high conservation of the catalytic domain across PRMT family members. We herein report 17zh (MS3-123), the first small-molecule, nanomolar covalent inhibitor targeting the unique Cys119 within the SAM-binding pocket of PRMT1 (IC50 = 11.4 nM) with over 17-96-fold selectivity against other type I PRMTs subfamily and >439-fold selectivity against type II PRMT5. 17zh selectively engages Cys119, inhibiting PRMT1 activity at both enzymatic and cellular levels. Functionally, 17zh suppressed breast cancer cell proliferation, migration, invasion, induced cell cycle arrest and apoptosis, and impaired tumor growth in vivo in the MDA-MB-231-xenograft model. Our findings establish 17zh as both a valuable chemical probe for PRMT1 research and a promising lead candidate for breast cancer treatment, highlighting the potential of covalent targeting for selective epigenetic drug discovery.
- 17 June 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69  (13) , 15423-15457
Unique Cysteine-Directed Covalent Inhibition of PRMT1 Suppresses Breast Tumorigenesis
Dysregulation of PRMT1, a key epigenetic enzyme, is strongly implicated in breast cancer pathogenesis. However, developing selective PRMT1 inhibitors has been challenging due to the high conservation of the catalytic domain across PRMT family members. We herein report 17zh (MS3-123), the first small-molecule, nanomolar covalent inhibitor targeting the unique Cys119 within the SAM-binding pocket of PRMT1 (IC50 = 11.4 nM) with over 17-96-fold selectivity against other type I PRMTs subfamily and >439-fold selectivity against type II PRMT5. 17zh selectively engages Cys119, inhibiting PRMT1 activity at both enzymatic and cellular levels. Functionally, 17zh suppressed breast cancer cell proliferation, migration, invasion, induced cell cycle arrest and apoptosis, and impaired tumor growth in vivo in the MDA-MB-231-xenograft model. Our findings establish 17zh as both a valuable chemical probe for PRMT1 research and a promising lead candidate for breast cancer treatment, highlighting the potential of covalent targeting for selective epigenetic drug discovery.
- 10 March 2026
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 148  (11) , 11450-11454
YY1 Interacts with Promoter R-Loops to Regulate Transcription
R-loops play critical roles in gene regulation and genome stability. To elucidate the protein-mediated mechanisms governing R-loop dynamics, we leveraged APEX-based proximity labeling to profile the R-loop proximal proteome. By integrating the proteomic data, bioinformatic predictions, and biochemical characterizations, we identified YY1 as an R-loop-binding protein. Localized R-loop induction at specific genomic loci via a CRISPR-dCas9/gRNA targeting system enhanced the local YY1 occupancy. Furthermore, integrated ChIP-seq and RNA-seq analyses revealed that promoter-associated YY1-R-loop interactions broadly regulate transcription. Together, our work identifies YY1 as a novel R-loop interaction protein and establishes a role for this interaction in modulating gene expression.
- 10 March 2026
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 148  (11) , 11450-11454
YY1 Interacts with Promoter R-Loops to Regulate Transcription
R-loops play critical roles in gene regulation and genome stability. To elucidate the protein-mediated mechanisms governing R-loop dynamics, we leveraged APEX-based proximity labeling to profile the R-loop proximal proteome. By integrating the proteomic data, bioinformatic predictions, and biochemical characterizations, we identified YY1 as an R-loop-binding protein. Localized R-loop induction at specific genomic loci via a CRISPR-dCas9/gRNA targeting system enhanced the local YY1 occupancy. Furthermore, integrated ChIP-seq and RNA-seq analyses revealed that promoter-associated YY1-R-loop interactions broadly regulate transcription. Together, our work identifies YY1 as a novel R-loop interaction protein and establishes a role for this interaction in modulating gene expression.
- Open Access
- 2 December 2025
- Published by Springer Nature in Communications Biology
- Vol. 9  (1)
Multi-omics elucidation of KDM5C, KDM6A, and KMT2B roles in cancer epigenetic dysregulation and transcriptional reprogramming
Histone-modifying enzymes (HMEs) are critical regulators of tumorigenesis through epigenetic reprogramming. While mutations in HMEs are recognized drivers of cancer epigenome dysregulation, systematic comparative analyses of their mutational impacts and functional divergence across malignancies remain underexplored. Here, we investigated three HMEs frequently mutated in diverse cancers: KMT2B (H3K4me3 methyltransferase), KDM5C (H3K4me3 demethylase), and KDM6A (H3K27me3 demethylase). Using CRISPR/Cas9-engineered HEK293T knockout cell lines, we performed integrated multi-omics profiling that combined genome-wide chromatin accessibility, transcriptomics, and chromatin-bound proteomics. Contrary to expectations that KMT2B loss (H3K4me3 depletion) and KDM5C loss (H3K4me3 accumulation) would induce opposing transcriptional programs, or that KDM6A deficiency (H3K27me3 accumulation) would exhibit distinct regulatory effects, our analyses revealed distinct effect of all three HME modulations in terms of both transcriptional output and chromatin-associated proteomic state. Functionally, KDM5C loss upregulated FOXF2 and downregulated KLF5, implicating the dysregulation of G protein–coupled receptor pathways; KDM6A loss upregulated JUNB and downregulated TP73, affecting extracellular matrix regulation; and KMT2B loss upregulated JUN and downregulated HOXA10, impacting on cytokine signaling. Notably, transcription factors such as PATZ1 and GATA2 were commonly altered across knockouts. In PANC-1 pancreatic cancer cells, we further confirmed that KDM6A regulates CDH family genes controlling cell adhesion, thereby promoting migration and invasion. Finally, integrative analyzes demonstrated strong correlations between promoter accessibility, transcription factor occupancy, and gene expression, and uncovered cooperation between epigenetic and genetic drivers. Together, these findings reveal context-dependent functional hierarchies among HMEs and underscore the necessity of multi-layered analyses to resolve the complexity of epigenetic regulation in cancer.
- 2 December 2025
- Published by Springer Nature in Communications Biology
- Vol. 9  (1)
Open AccessMulti-omics elucidation of KDM5C, KDM6A, and KMT2B roles in cancer epigenetic dysregulation and transcriptional reprogramming
Histone-modifying enzymes (HMEs) are critical regulators of tumorigenesis through epigenetic reprogramming. While mutations in HMEs are recognized drivers of cancer epigenome dysregulation, systematic comparative analyses of their mutational impacts and functional divergence across malignancies remain underexplored. Here, we investigated three HMEs frequently mutated in diverse cancers: KMT2B (H3K4me3 methyltransferase), KDM5C (H3K4me3 demethylase), and KDM6A (H3K27me3 demethylase). Using CRISPR/Cas9-engineered HEK293T knockout cell lines, we performed integrated multi-omics profiling that combined genome-wide chromatin accessibility, transcriptomics, and chromatin-bound proteomics. Contrary to expectations that KMT2B loss (H3K4me3 depletion) and KDM5C loss (H3K4me3 accumulation) would induce opposing transcriptional programs, or that KDM6A deficiency (H3K27me3 accumulation) would exhibit distinct regulatory effects, our analyses revealed distinct effect of all three HME modulations in terms of both transcriptional output and chromatin-associated proteomic state. Functionally, KDM5C loss upregulated FOXF2 and downregulated KLF5, implicating the dysregulation of G protein–coupled receptor pathways; KDM6A loss upregulated JUNB and downregulated TP73, affecting extracellular matrix regulation; and KMT2B loss upregulated JUN and downregulated HOXA10, impacting on cytokine signaling. Notably, transcription factors such as PATZ1 and GATA2 were commonly altered across knockouts. In PANC-1 pancreatic cancer cells, we further confirmed that KDM6A regulates CDH family genes controlling cell adhesion, thereby promoting migration and invasion. Finally, integrative analyzes demonstrated strong correlations between promoter accessibility, transcription factor occupancy, and gene expression, and uncovered cooperation between epigenetic and genetic drivers. Together, these findings reveal context-dependent functional hierarchies among HMEs and underscore the necessity of multi-layered analyses to resolve the complexity of epigenetic regulation in cancer.
- Top Cited Papers
- 12 August 2025
- Published by Springer Nature in Nature Biomedical Engineering
- Vol. 10  (3) , 473-489
In vivo genome editing of human haematopoietic stem cells for treatment of blood disorders using mRNA delivery
Ex vivo autologous haematopoietic stem cell (HSC) gene therapy provides a promising treatment option for haematological disorders. However, current methods involve complex processes and chemotherapeutic conditioning, leading to limited accessibility for treatment and major side effects. Here we develop antibody-free targeted lipid nanoparticles (LNPs) for mRNA delivery to HSCs in vivo, enabling efficient base editing of the γ-globin gene (HBG1/2) promoter target in human HSCs to reactivate fetal haemoglobin in derived erythroid cells. Delivery of ABE8e/sgRNA mRNA with optimized LNPs achieves efficient in vivo base editing of HBG1/2 in transfusion-dependent β-thalassaemia (TDT) patient-derived HSCs engrafted in immunodeficient NCG-X mice, showing restored globin chain balance in erythroid cells. Our research indicates that using LNPs for genome editor delivery achieves efficient editing of endogenous genes of human HSCs. This non-viral delivery system eliminates the need for collecting or mobilizing HSCs, providing a potent and one-time treatment potential for blood disorders such as sickle cell disease and TDT.
- 12 August 2025
- Published by Springer Nature in Nature Biomedical Engineering
- Vol. 10  (3) , 473-489
Top Cited PapersIn vivo genome editing of human haematopoietic stem cells for treatment of blood disorders using mRNA delivery
Ex vivo autologous haematopoietic stem cell (HSC) gene therapy provides a promising treatment option for haematological disorders. However, current methods involve complex processes and chemotherapeutic conditioning, leading to limited accessibility for treatment and major side effects. Here we develop antibody-free targeted lipid nanoparticles (LNPs) for mRNA delivery to HSCs in vivo, enabling efficient base editing of the γ-globin gene (HBG1/2) promoter target in human HSCs to reactivate fetal haemoglobin in derived erythroid cells. Delivery of ABE8e/sgRNA mRNA with optimized LNPs achieves efficient in vivo base editing of HBG1/2 in transfusion-dependent β-thalassaemia (TDT) patient-derived HSCs engrafted in immunodeficient NCG-X mice, showing restored globin chain balance in erythroid cells. Our research indicates that using LNPs for genome editor delivery achieves efficient editing of endogenous genes of human HSCs. This non-viral delivery system eliminates the need for collecting or mobilizing HSCs, providing a potent and one-time treatment potential for blood disorders such as sickle cell disease and TDT.
- 17 July 2025
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 97  (29) , 16011-16018
Proteome-Wide Identification of O6-Methyl-2’-deoxyguanosine-Binding Proteins
DNA is subjected to damage from various endogenous and exogenous sources of alkylating agents, resulting in alkylated DNA lesions. Among these lesions, O6-methyl-2'-deoxyguanosine (O6-Me-dG) is highly mutagenic, and it can be repaired by O6-alkylguanine DNA alkyltransferase and mismatch repair pathway. It, however, remains unclear whether O6-Me-dG in DNA can be recognized by other cellular proteins. Here, we employed a quantitative mass spectrometry-based approach to uncover reader proteins of O6-Me-dG in DNA when it is paired with a 2'-deoxycytidine (dC) or thymidine (dT). We were able to identify 67 and 31 candidate reader proteins for duplex DNA harboring O6-Me-dG:dC and O6-Me-dG:dT base pairs, respectively. In addition, genetic ablation of CDKN2AIP, a.k.a. CARF, one of those proteins that can recognize both the O6-Me-dG:dC and O6-Me-dG:dT base pairs, in HEK293T cells conferred augmented tolerance to N-nitroso-N-methylurea (NMU), an alkylating agent that can induce O6-Me-dG in DNA. Accordingly, our LC-MS/MS quantification results revealed that the loss of CDKN2AIP led to diminished accumulation of NMU-induced O6-Me-dG in genomic DNA. Together, we explored the damage recognition proteins of O6-Me-dG using a quantitative mass spectrometry-based approach, and our results revealed an unexpected role of CDKN2AIP in sensitizing cultured cells toward a DNA methylating agent.
- 17 July 2025
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 97  (29) , 16011-16018
Proteome-Wide Identification of O6-Methyl-2’-deoxyguanosine-Binding Proteins
DNA is subjected to damage from various endogenous and exogenous sources of alkylating agents, resulting in alkylated DNA lesions. Among these lesions, O6-methyl-2'-deoxyguanosine (O6-Me-dG) is highly mutagenic, and it can be repaired by O6-alkylguanine DNA alkyltransferase and mismatch repair pathway. It, however, remains unclear whether O6-Me-dG in DNA can be recognized by other cellular proteins. Here, we employed a quantitative mass spectrometry-based approach to uncover reader proteins of O6-Me-dG in DNA when it is paired with a 2'-deoxycytidine (dC) or thymidine (dT). We were able to identify 67 and 31 candidate reader proteins for duplex DNA harboring O6-Me-dG:dC and O6-Me-dG:dT base pairs, respectively. In addition, genetic ablation of CDKN2AIP, a.k.a. CARF, one of those proteins that can recognize both the O6-Me-dG:dC and O6-Me-dG:dT base pairs, in HEK293T cells conferred augmented tolerance to N-nitroso-N-methylurea (NMU), an alkylating agent that can induce O6-Me-dG in DNA. Accordingly, our LC-MS/MS quantification results revealed that the loss of CDKN2AIP led to diminished accumulation of NMU-induced O6-Me-dG in genomic DNA. Together, we explored the damage recognition proteins of O6-Me-dG using a quantitative mass spectrometry-based approach, and our results revealed an unexpected role of CDKN2AIP in sensitizing cultured cells toward a DNA methylating agent.
- Open Access
Identification of SMARCA1 as a key regulator for Colorectal Cancer
Emerging evidence indicates that aberrations in the writing, reading, or erasure of chromatin modification codes are pivotal events in various human cancers. In this study, we conducted a systematic investigation of histone modification recognition proteins in a pair of colorectal cancer cell lines, SW480 and SW620. Using chromatin fractionation combined with data-independent acquisition mass spectrometry (DIA-MS), we developed a robust method to identify changes in histone modification recognition proteins during cancer progression. Our analysis revealed 22 proteins that were significantly upregulated and 22 proteins that were significantly downregulated in SW620 cells compared to SW480 cells. Notably, SMARCA1, a member of the ISWI family belonging to ATP-dependent chromatin remodeling complexes, was downregulated in SW620 cells compared to SW480 cells. Its high expression was strongly correlated with poor patient prognosis, aligning with the proposed role of SMARCA1 in promoting colorectal cancer (CRC) metastasis. Furthermore, reduced SMARCA1 expression altered the levels of metastasis-related matrix metalloproteinases (MMPs) in these cells. In conclusion, by systematically profiling histone modification recognition proteins in a matched pair of primary and metastatic CRC cell lines, we identified SMARCA1 as a potential driver of CRC metastasis and a promising therapeutic target for CRC patients.
Open AccessIdentification of SMARCA1 as a key regulator for Colorectal Cancer
Emerging evidence indicates that aberrations in the writing, reading, or erasure of chromatin modification codes are pivotal events in various human cancers. In this study, we conducted a systematic investigation of histone modification recognition proteins in a pair of colorectal cancer cell lines, SW480 and SW620. Using chromatin fractionation combined with data-independent acquisition mass spectrometry (DIA-MS), we developed a robust method to identify changes in histone modification recognition proteins during cancer progression. Our analysis revealed 22 proteins that were significantly upregulated and 22 proteins that were significantly downregulated in SW620 cells compared to SW480 cells. Notably, SMARCA1, a member of the ISWI family belonging to ATP-dependent chromatin remodeling complexes, was downregulated in SW620 cells compared to SW480 cells. Its high expression was strongly correlated with poor patient prognosis, aligning with the proposed role of SMARCA1 in promoting colorectal cancer (CRC) metastasis. Furthermore, reduced SMARCA1 expression altered the levels of metastasis-related matrix metalloproteinases (MMPs) in these cells. In conclusion, by systematically profiling histone modification recognition proteins in a matched pair of primary and metastatic CRC cell lines, we identified SMARCA1 as a potential driver of CRC metastasis and a promising therapeutic target for CRC patients.
- Open Access
- 13 June 2024
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 52  (13) , 7401-7413
YY1 is involved in homologous recombination inhibition at guanine quadruplex sites in human cells
Homologous recombination (HR) is a key process for repairing DNA double strand breaks and for promoting genetic diversity. However, HR occurs unevenly across the genome, and certain genomic features can influence its activity. One such feature is the presence of guanine quadruplexes (G4s), stable secondary structures widely distributed throughout the genome. These G4s play essential roles in gene transcription and genome stability regulation. Especially, elevated G4 levels in cells deficient in the Bloom syndrome helicase (BLM) significantly enhance HR at G4 sites, potentially threatening genome stability. Here, we investigated the role of G4-binding protein Yin Yang-1 (YY1) in modulating HR at G4 sites in human cells. Our results show that YY1’s binding to G4 structures suppresses sister chromatid exchange after BLM knockdown, and YY1’s chromatin occupancy negatively correlates with the overall HR rate observed across the genome. By limiting RAD51 homolog 1 (RAD51) access, YY1 preferentially binds to essential genomic regions, shielding them from excessive HR. Our findings unveil a novel role of YY1–G4 interaction, revealing novel insights into cellular mechanisms involved in HR regulation.
- 13 June 2024
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 52  (13) , 7401-7413
Open AccessYY1 is involved in homologous recombination inhibition at guanine quadruplex sites in human cells
Homologous recombination (HR) is a key process for repairing DNA double strand breaks and for promoting genetic diversity. However, HR occurs unevenly across the genome, and certain genomic features can influence its activity. One such feature is the presence of guanine quadruplexes (G4s), stable secondary structures widely distributed throughout the genome. These G4s play essential roles in gene transcription and genome stability regulation. Especially, elevated G4 levels in cells deficient in the Bloom syndrome helicase (BLM) significantly enhance HR at G4 sites, potentially threatening genome stability. Here, we investigated the role of G4-binding protein Yin Yang-1 (YY1) in modulating HR at G4 sites in human cells. Our results show that YY1’s binding to G4 structures suppresses sister chromatid exchange after BLM knockdown, and YY1’s chromatin occupancy negatively correlates with the overall HR rate observed across the genome. By limiting RAD51 homolog 1 (RAD51) access, YY1 preferentially binds to essential genomic regions, shielding them from excessive HR. Our findings unveil a novel role of YY1–G4 interaction, revealing novel insights into cellular mechanisms involved in HR regulation.
- Open Access
- 15 March 2024
- Published by Elsevier in Chemical Engineering Journal Advances
- Vol. 18, 100599
Evaluating bottle liquid-liquid extraction technique for monitoring residual levels of organochlorine pesticides in wastewater treatment-associated matrices
- 15 March 2024
- Published by Elsevier in Chemical Engineering Journal Advances
- Vol. 18, 100599
Open AccessEvaluating bottle liquid-liquid extraction technique for monitoring residual levels of organochlorine pesticides in wastewater treatment-associated matrices